Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.255 USD | +0.67% | +2.50% | -29.09% |
04/06 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
15/05 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.09% | 1.82Cr | |
+23.13% | 5.27TCr | |
+37.49% | 3.9TCr | |
-8.73% | 3.85TCr | |
+28.09% | 3.04TCr | |
-12.26% | 2.64TCr | |
+10.57% | 2.61TCr | |
+45.05% | 1.42TCr | |
+32.23% | 1.26TCr | |
-6.56% | 1.15TCr |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Jefferies Downgrades Lumos Pharma to Hold From Buy With $7 Price Target